Novartis Series A1 Preferred Stock Financing
In August 2012, our lawyers represented Novartis Bioventures in the issuance of Series A1 Preferred Stock of Aerpio Therapeutics, Inc. Aerpio Therapeutics, Inc., based in Cincinnati, Ohio, is a clinical-stage biopharmaceutical company that engages in the development of therapies for vascular diseases. Novartis Bioventures, is a venture fund based in Cambridge, Massachusetts.
Posted on August 28, 2012
Disclaimer
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.